Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Minnesota: - Minnesota Oncology Hematology PA-Chaska — Chaska, Minnesota
- Fairview Clinics and Surgery Center Maple Grove — Maple Grove, Minnesota
- Hennepin County Medical Center — Minneapolis, Minnesota
- University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
- Monticello Cancer Center — Monticello, Minnesota
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…
Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Minnesota Oncology - Burnsville — Burnsville, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
- Minnesota Oncology - Coon Rapids — Coon Rapids, Minnesota
- Fairview Southdale Hospital — Edina, Minnesota
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Minnesota: - Children's Hospitals and Clinics of Minnesota - Minneapolis — Minneapolis, Minnesota
- University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
- Mayo Clinic in Rochester — Rochester, Minnesota
Phase 3 Recruiting Industry
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Minnesota: - University of Minnesota — Minneapolis, Minnesota
- Mayo Clinic - Cancer Center - Rochester — Rochester, Minnesota
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Minnesota: - Allina Health Systems/Abbott Northwestern Hospital — Minneapolis, Minnesota
- Mayo Clinic Cancer Center - Rochester — Rochester, Minnesota
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in Minnesota: - Masonic Cancer Center, University of Minnesota — Minneapolis, Minnesota
- Mayo Clinic - Rochester — Rochester, Minnesota
Phase 3 Recruiting Industry
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also imper…
Sponsor: CarThera
NCT ID: NCT05902169
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects and how well stereotactic radiosurgery (SRS) works before or after surgery in patients with tumors that has spread to the brain or that can be removed by surgery. Stereotactic radiosurgery is a…
Sponsor: Mayo Clinic
NCT ID: NCT03750227
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Minnesota: - Fairview Ridges Hospital — Burnsville, Minnesota
- Minnesota Oncology - Burnsville — Burnsville, Minnesota
- Cambridge Medical Center — Cambridge, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
- Fairview Southdale Hospital — Edina, Minnesota
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Minnesota: - Children's Hospitals and Clinics of Minnesota - Minneapolis — Minneapolis, Minnesota
- Mayo Clinic in Rochester — Rochester, Minnesota
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Minnesota: - St. Luke's Hospital — Duluth, Minnesota
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Minnesota: - Masonic Cancer Center University of Minnesota — Minneapolis, Minnesota
Phase 2 Recruiting Academic/Other
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes…
Sponsor: University of California, San Francisco
NCT ID: NCT05009992
Sites in Minnesota: - Children's Hospital Minnesota — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the secon…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06810544
Sites in Minnesota: - Mayo Clinic Cancer Center — Rochester, Minnesota
Phase 2 Recruiting Academic/Other
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (a…
Sponsor: David Reardon, MD
NCT ID: NCT02977780
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 2 Recruiting Industry
The purpose of this research is to test an investigational device using ultrasound along with an investigational drug to see if it is useful in treating glioblastoma following standard of care therapy surgery and chemoradiation. This study…
Sponsor: Alpheus Medical, Inc.
NCT ID: NCT07225621
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 2 Recruiting Academic/Other
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT05535166
Sites in Minnesota: - Children's Hospital and Clinics of Minnesota — Minneapolis, Minnesota
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of single fraction stereotactic radiosurgery to fractionated stereotactic radiosurgery for the treatment of patients with cancer that has spread to the brain (metastatic brain disease). Stereotactic …
Sponsor: Mayo Clinic
NCT ID: NCT05222620
Sites in Minnesota: - Mayo Clinic Health System in Albert Lea — Albert Lea, Minnesota
- Mayo Clinic Health Systems-Mankato — Mankato, Minnesota
- Mayo Clinic in Rochester — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with your standard…
Sponsor: Myosin Therapeutics Inc.
NCT ID: NCT07185880
Sites in Minnesota: - Mayo Clinic Hospital — Rochester, Minnesota
Phase 2 Recruiting Academic/Other
This phase II trial tests how well retifanlimab with bevacizumab and hypofractionated radiotherapy, compared to bevacizumab and hypofractionated radiotherapy alone, works in treating patients with glioblastoma that has come back after a pe…
Sponsor: Academic and Community Cancer Research United
NCT ID: NCT06160206
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of adding WSD0922-FU to temozolomide versus temozolomide alone in slowing disease progression in patients with Epidermal Growth Factor Receptor (EGFR)-mutant, IDH-wildtype glioblastoma. Temozolomide …
Sponsor: Mayo Clinic
NCT ID: NCT07708961
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
The goal of this interventional study is to evaluate the efficacy of APG-157 in combination with Bevacizumab in subjects with recurrent high-grade glioma. The main questions the study aims to answer are: * Progression-free and overall surv…
Sponsor: Aveta Biomics, Inc.
NCT ID: NCT06011109
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 2 Recruiting Academic/Other
This phase II trial studies the clinical outcomes of hypofractionated radiation therapy in patients with diffuse midline gliomas. This study aims to change the way radiation is delivered, from giving 6 weeks of radiation all at once to giv…
Sponsor: Mayo Clinic
NCT ID: NCT05077735
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 2 Recruiting Academic/Other
This clinical trial evaluates whether gallium-68 (Ga-68) prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) imaging is useful in differentiating between disease that has come back after…
Sponsor: Mayo Clinic
NCT ID: NCT06444412
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota